Primary-source record
Larimar completed its rolling BLA submission seeking accelerated approval of nomlabofusp based on skin frataxin as a potential novel surrogate endpoint, supported by open-label data showing sustained frataxin increases and directional clinical improvements. FDA previously aligned on the data package and surrogate endpoint approach. This advances the regulatory path with BLA acceptance expected in early 2027 and potential U.S. approval in mid-2027.
EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA • Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint • Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population • Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp Bala Cynwyd, PA, November 9, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich’s ataxia (FA). Nomlabofusp is an investigational protein replacement therapy designed to address the underlying cause of FA, frataxin deficiency, by delivering human frataxin to mitochondria. Completion of the submission follows previously disclosed FDA feedback
Larimar receives Breakthrough Therapy Designation for nomlabofusp in FA
Larimar: FDA grants Breakthrough Therapy Designation to nomlabofusp in FA